FDA Panel on Peptide Compounding Set for July 23-24, Critical for Hims' GLP-1 Business
HIMS has more than doubled off its 52-week low of $13.74.
Summary
An FDA panel is scheduled for July 23-24 to discuss adding peptides to 503A, a regulatory decision critical for Hims & Hers Health's compounded GLP-1 product offerings. This follows earlier news on April 16th regarding the FDA's general consideration of easing restrictions on compounding pharmacies for peptides, now with a specific date for review. Separately, analysts raised price targets for HIMS, with Barclays to $39 and Leerink to $25. The outcome of the July FDA panel will be a key factor to watch for the company's weight loss segment.
At the time of this announcement, HIMS was trading at $32.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.